Fasting glucagon-like peptide 1 concentration is associated with lower carbohydrate intake and increases with overeating.
Ad libitum food intake
Carbohydrates intake
Glucagon-like peptide 1
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
09
08
2018
accepted:
14
09
2018
pubmed:
5
10
2018
medline:
21
8
2019
entrez:
5
10
2018
Statut:
ppublish
Résumé
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that appears to play a major role in the control of food intake. The aim of this investigation was to evaluate and quantify the association of circulating GLP-1 concentration with ad libitum total calorie and macronutrient intake. One-hundred and fifteen individuals (72 men) aged 35 ± 10 years were admitted for an inpatient study investigating the determinants of energy intake. Ad libitum food intake was assessed during 3 days using a reproducible vending machine paradigm. Fasting plasma GLP-1 concentrations were measured on the morning of the first day and on the morning of the fourth day after ad libitum feeding. Plasma GLP-1 concentrations increased by 14% after 3 days of ad libitum food intake. Individuals overate on average 139 ± 45% of weight-maintaining energy needs. Fasting plasma GLP-1 on day 1 was negatively associated with carbohydrate intake (r = - 0.2, p = 0.03) and with daily energy intake from low fat-high simple sugar (r = - 0.22, p = 0.016). Higher plasma GLP-1 concentrations prior to ad libitum food intake were associated with lower carbohydrate intake and lower simple sugar ingestion, indicating a possible role of the GLP-1 in the reward pathway regulating simple sugar intake. ClinicalTrials.gov identifier: NCT00342732.
Identifiants
pubmed: 30284224
doi: 10.1007/s40618-018-0954-5
pii: 10.1007/s40618-018-0954-5
pmc: PMC6447483
mid: NIHMS1508768
doi:
Substances chimiques
Carbohydrates
0
Glucagon-Like Peptide 1
89750-14-1
Banques de données
ClinicalTrials.gov
['NCT00342732']
Types de publication
Journal Article
Langues
eng
Pagination
557-566Subventions
Organisme : Intramural NIH HHS
ID : ZIA DK069091-12
Pays : United States
Organisme : National Institutes of Health
ID : Z99 DK999999
Références
Int J Obes Relat Metab Disord. 1999 Mar;23(3):304-11
pubmed: 10193877
Br J Nutr. 2000 Mar;83 Suppl 1:S17-20
pubmed: 10889787
J Clin Endocrinol Metab. 2001 Sep;86(9):4382-9
pubmed: 11549680
Lancet. 2002 Mar 9;359(9309):824-30
pubmed: 11897280
Int J Obes Relat Metab Disord. 2003 Nov;27(11):1359-64
pubmed: 14574347
Brain Res. 2005 May 17;1044(1):127-31
pubmed: 15862798
Annu Rev Nutr. 2007;27:389-414
pubmed: 17444812
Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):14887-8
pubmed: 17855558
Physiol Rev. 2007 Oct;87(4):1409-39
pubmed: 17928588
Curr Opin Pharmacol. 2007 Dec;7(6):607-12
pubmed: 18037344
Annu Rev Psychol. 2008;59:55-92
pubmed: 18154499
J Neurochem. 2008 Jul;106(1):455-63
pubmed: 18397368
Diabetes. 2008 Aug;57(8):2046-54
pubmed: 18487451
Diabetologia. 2008 Dec;51(12):2263-70
pubmed: 18795252
Endocrinology. 2009 Jun;150(6):2654-9
pubmed: 19264875
J Physiol. 2009 May 15;587(Pt 10):2387-97
pubmed: 19332493
Am J Clin Nutr. 2010 Feb;91(2):343-8
pubmed: 19923376
Am J Clin Nutr. 1991 Jun;53(6):1368-71
pubmed: 2035463
N Engl J Med. 2011 Feb 24;364(8):719-29
pubmed: 21345101
Clin Chim Acta. 2011 Jun 11;412(13-14):1191-4
pubmed: 21414305
Front Neurosci. 2011 Mar 03;5:23
pubmed: 21519398
J Addict Med. 2009 Mar;3(1):8-18
pubmed: 21603099
Int J Obes (Lond). 2012 Jun;36(6):843-54
pubmed: 21844879
Am J Physiol Regul Integr Comp Physiol. 2011 Nov;301(5):R1479-85
pubmed: 21849636
Obesity (Silver Spring). 2012 Feb;20(2):313-7
pubmed: 22134200
Clin Endocrinol (Oxf). 2013 Feb;78(2):217-25
pubmed: 22324306
J Neurosci. 2012 Apr 4;32(14):4812-20
pubmed: 22492036
PLoS One. 2012;7(5):e36225
pubmed: 22629311
Nutr Metab (Lond). 2013 Apr 08;10(1):33
pubmed: 23566334
Eur J Endocrinol. 2013 Sep 12;169(4):421-30
pubmed: 23864340
Metabolism. 2014 Feb;63(2):226-32
pubmed: 24290838
J Diabetes Investig. 2010 Apr 22;1(1-2):56-9
pubmed: 24843409
PLoS One. 2015 Mar 20;10(3):e0119034
pubmed: 25793511
J Clin Endocrinol Metab. 2015 Aug;100(8):3011-20
pubmed: 26086330
Br J Nutr. 2017 Jan;117(1):48-55
pubmed: 28115026
Neurosci Biobehav Rev. 2017 Sep;80:457-475
pubmed: 28669754
Lancet. 1987 Dec 5;2(8571):1300-4
pubmed: 2890903
J Endocrinol Invest. 2018 Apr;41(4):439-445
pubmed: 28975572
Metabolism. 2018 Aug;85:116-125
pubmed: 29596853
Diabetes Care. 1997 Jul;20(7):1183-97
pubmed: 9203460
J Clin Invest. 1998 Feb 1;101(3):515-20
pubmed: 9449682
Physiol Behav. 1998 Mar;63(5):919-28
pubmed: 9618017
J Comp Neurol. 1999 Jan 11;403(2):261-80
pubmed: 9886047